O	0	10	Clinically
O	11	19	relevant
B-condition	20	31	pneumonitis
O	32	37	after
O	38	48	sequential
B-intervention	49	59	paclitaxel
I-intervention	59	60	-
I-intervention	60	65	based
I-intervention	66	78	chemotherapy
I-intervention	79	82	and
I-intervention	83	95	radiotherapy
O	96	98	in
O	99	105	breast
O	106	112	cancer
O	113	121	patients
O	121	122	.

O	123	129	Taxane
O	129	130	-
O	130	135	based
O	136	148	chemotherapy
O	149	152	has
O	153	157	been
O	158	168	associated
O	169	173	with
O	174	176	an
O	177	186	increased
O	187	191	risk
O	192	194	of
O	195	204	radiation
O	205	216	pneumonitis
O	217	219	in
O	220	228	patients
O	229	233	with
O	234	240	breast
O	241	247	cancer
O	247	248	.

O	249	251	To
O	252	258	obtain
O	259	269	additional
O	270	281	information
O	282	287	about
O	288	292	this
O	293	304	association
O	304	305	,
O	306	308	we
O	309	321	investigated
O	322	325	the
O	326	337	association
O	338	345	between
O	346	356	paclitaxel
O	357	369	chemotherapy
O	370	373	and
O	374	383	radiation
O	384	395	pneumonitis
O	396	398	in
O	399	407	patients
O	408	421	participating
O	422	424	in
O	425	426	a
O	427	432	phase
O	433	436	III
O	437	447	randomized
O	448	453	study
O	453	454	.

B-total-participants	455	459	Five
I-total-participants	460	467	hundred
I-total-participants	468	471	and
I-total-participants	472	478	twenty
I-total-participants	478	479	-
I-total-participants	479	483	four
B-eligibility	484	490	breast
I-eligibility	491	497	cancer
I-eligibility	498	506	patients
O	507	511	were
O	512	525	prospectively
O	526	529	and
O	530	538	randomly
O	539	547	assigned
O	548	550	to
O	551	558	receive
O	559	565	either
O	566	570	four
O	571	577	cycles
O	578	580	of
O	581	591	paclitaxel
O	592	600	followed
O	601	603	by
O	604	608	four
O	609	615	cycles
O	616	618	of
O	619	620	5
O	620	621	-
O	621	633	fluorouracil
O	633	634	,
O	635	646	doxorubicin
O	646	647	,
O	648	664	cyclophosphamide
O	665	666	(
O	666	669	FAC
O	669	670	)
O	671	673	or
B-control	674	679	eight
I-control	680	686	cycles
I-control	687	689	of
I-control	690	693	FAC
O	693	694	.

B-total-participants	695	698	One
I-total-participants	699	706	hundred
I-total-participants	707	710	and
I-total-participants	711	717	eighty
I-total-participants	717	718	-
I-total-participants	718	722	nine
O	723	725	of
O	726	731	these
O	732	740	patients
O	741	742	(
B-intervention-participants	742	745	100
O	746	748	in
O	749	752	the
O	753	763	paclitaxel
O	763	764	-
O	764	767	FAC
O	768	773	group
O	774	777	and
B-control-participants	778	780	89
O	781	783	in
O	784	787	the
O	788	791	FAC
O	792	797	group
O	797	798	)
O	799	811	subsequently
O	812	821	underwent
O	822	831	radiation
O	832	839	therapy
O	840	842	in
O	843	846	our
O	847	858	institution
O	859	862	and
O	863	866	had
O	867	874	medical
O	875	882	records
O	883	892	available
O	893	895	to
O	896	902	review
O	903	906	for
O	907	916	pulmonary
O	917	925	symptoms
O	925	926	.

O	927	929	In
O	930	938	addition
O	938	939	,
O	940	941	a
O	942	953	radiologist
O	954	957	who
O	958	961	was
O	962	969	unaware
O	970	972	of
O	973	976	the
O	977	981	type
O	982	984	of
O	985	994	treatment
O	995	1001	scored
O	1002	1007	chest
O	1008	1009	x
O	1009	1010	-
O	1010	1013	ray
O	1014	1021	changes
O	1022	1027	after
O	1028	1037	radiation
O	1038	1047	treatment
O	1047	1048	.

O	1049	1054	Crude
O	1055	1060	rates
O	1061	1063	of
O	1064	1073	radiation
O	1074	1085	pneumonitis
O	1086	1090	were
O	1091	1099	compared
O	1100	1104	with
O	1105	1108	chi
O	1108	1109	-
O	1109	1115	square
O	1116	1118	or
O	1119	1125	Fisher
O	1125	1126	'
O	1126	1127	s
O	1128	1133	exact
O	1134	1138	test
O	1138	1139	,
O	1140	1143	and
O	1144	1153	actuarial
O	1154	1159	rates
O	1160	1164	were
O	1165	1173	assessed
O	1174	1178	with
O	1179	1185	Kaplan
O	1185	1186	-
O	1186	1191	Meier
O	1192	1195	and
O	1196	1199	log
O	1199	1200	-
O	1200	1204	rank
O	1205	1210	tests
O	1210	1211	.

O	1212	1215	All
O	1216	1227	statistical
O	1228	1233	tests
O	1234	1238	were
O	1239	1242	two
O	1242	1243	-
O	1243	1248	sided
O	1248	1249	.

O	1250	1252	No
O	1253	1263	difference
O	1264	1266	in
O	1267	1270	the
B-outcome	1271	1275	rate
I-outcome	1276	1278	of
I-outcome	1279	1289	clinically
I-outcome	1290	1298	relevant
I-outcome	1299	1308	radiation
I-outcome	1309	1320	pneumonitis
O	1321	1324	was
O	1325	1333	observed
O	1334	1341	between
O	1342	1345	the
O	1346	1349	two
O	1350	1356	groups
O	1357	1358	(
B-iv-bin-percent	1358	1359	5
I-iv-bin-percent	1359	1360	.
I-iv-bin-percent	1360	1361	0
I-iv-bin-percent	1361	1362	%
O	1363	1365	in
O	1366	1369	the
O	1370	1380	paclitaxel
O	1380	1381	-
O	1381	1384	FAC
O	1385	1390	group
O	1391	1397	versus
B-cv-bin-percent	1398	1399	4
I-cv-bin-percent	1399	1400	.
I-cv-bin-percent	1400	1401	5
I-cv-bin-percent	1401	1402	%
O	1403	1405	in
O	1406	1409	the
O	1410	1413	FAC
O	1414	1419	group
O	1419	1420	;
O	1421	1431	difference
O	1432	1433	=
O	1434	1435	0
O	1435	1436	.
O	1436	1437	5
O	1437	1438	%
O	1438	1439	,
O	1440	1442	95
O	1442	1443	%
O	1444	1446	CI
O	1447	1448	=
O	1449	1450	-
O	1450	1451	6
O	1451	1452	.
O	1452	1453	6
O	1453	1454	%
O	1455	1457	to
O	1458	1459	5
O	1459	1460	.
O	1460	1461	5
O	1461	1462	%
O	1462	1463	;
O	1464	1465	P
O	1466	1467	=
O	1468	1469	1
O	1469	1470	.
O	1470	1472	00
O	1472	1473	)
O	1473	1474	.

B-outcome	1475	1479	Oral
I-outcome	1480	1488	steroids
I-outcome	1489	1492	for
I-outcome	1493	1504	pneumonitis
O	1505	1509	were
O	1510	1515	taken
O	1516	1518	by
B-iv-bin-abs	1519	1522	two
O	1523	1531	patients
O	1532	1534	in
O	1535	1538	the
O	1539	1549	paclitaxel
O	1549	1550	-
O	1550	1553	FAC
O	1554	1559	group
O	1560	1563	but
O	1564	1566	by
B-cv-bin-abs	1567	1571	none
O	1572	1574	in
O	1575	1578	the
O	1579	1582	FAC
O	1583	1588	group
O	1588	1589	,
O	1590	1593	and
O	1594	1596	no
O	1597	1604	patient
O	1605	1608	was
B-outcome	1609	1621	hospitalized
I-outcome	1622	1625	for
I-outcome	1626	1628	or
I-outcome	1629	1633	died
I-outcome	1634	1636	of
I-outcome	1637	1646	radiation
I-outcome	1647	1658	pneumonitis
O	1658	1659	.

O	1660	1663	The
O	1664	1674	paclitaxel
O	1674	1675	-
O	1675	1678	FAC
O	1679	1684	group
O	1685	1686	(
B-iv-bin-percent	1686	1688	39
I-iv-bin-percent	1688	1689	.
I-iv-bin-percent	1689	1690	3
I-iv-bin-percent	1690	1691	%
O	1691	1692	)
O	1693	1696	had
O	1697	1698	a
O	1699	1705	higher
B-outcome	1706	1710	rate
I-outcome	1711	1713	of
I-outcome	1714	1726	radiographic
I-outcome	1727	1734	changes
I-outcome	1735	1740	after
I-outcome	1741	1752	irradiation
O	1753	1757	than
O	1758	1761	the
O	1762	1765	FAC
O	1766	1771	group
O	1772	1773	(
B-cv-bin-percent	1773	1775	23
I-cv-bin-percent	1775	1776	.
I-cv-bin-percent	1776	1777	7
I-cv-bin-percent	1777	1778	%
O	1778	1779	;
O	1780	1790	difference
O	1791	1792	=
O	1793	1795	15
O	1795	1796	.
O	1796	1797	6
O	1797	1798	%
O	1798	1799	,
O	1800	1802	95
O	1802	1803	%
O	1804	1806	CI
O	1807	1808	=
O	1809	1810	-
O	1810	1811	0
O	1811	1812	.
O	1812	1814	11
O	1814	1815	%
O	1816	1818	to
O	1819	1821	28
O	1821	1822	.
O	1822	1823	8
O	1823	1824	%
O	1824	1825	;
O	1826	1827	P
O	1828	1829	=
O	1830	1831	.
O	1831	1834	034
O	1834	1835	)
O	1835	1836	.

O	1837	1845	Patients
O	1846	1850	with
O	1851	1857	breast
O	1858	1864	cancer
O	1865	1872	treated
O	1873	1877	with
O	1878	1888	sequential
O	1889	1899	paclitaxel
O	1899	1900	,
O	1901	1904	FAC
O	1904	1905	,
O	1906	1909	and
O	1910	1919	radiation
O	1920	1927	therapy
O	1928	1936	appeared
O	1937	1939	to
O	1940	1944	have
O	1945	1946	a
O	1947	1951	very
O	1952	1955	low
O	1956	1960	rate
O	1961	1963	of
O	1964	1974	clinically
O	1975	1983	relevant
O	1984	1993	radiation
O	1994	2005	pneumonitis
O	2006	2010	that
O	2011	2014	was
O	2015	2017	no
O	2018	2027	different
O	2028	2032	from
O	2033	2037	that
O	2038	2040	of
O	2041	2049	patients
O	2050	2057	treated
O	2058	2062	with
O	2063	2066	FAC
O	2067	2072	alone
O	2072	2073	.
